DEDyadin Esharif

Dyadin Esharif

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dyadin Esharif has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Jason M. Shapiro

    Division of Pediatric Gastroenterology, Nutrition and Liver Diseases Hasbro Children's Hospital of Rhode Island Hospital Providence Rhode Island USA

    1 shared publication
  • Michael Herzlinger

    Division of Pediatric Gastroenterology, Nutrition and Liver Diseases, Hasbro Children's Hospital and Department of Pediatrics, Warren Alpert Medical School of Brown University, Providence, RI, USA

    1 shared publication
  • Muhammad Safwan Riaz

    Division of Pediatric Gastroenterology, Nutrition and Liver Diseases, Hasbro Children's Hospital and Department of Pediatrics, Warren Alpert Medical School of Brown University, Providence, RI, USA

    1 shared publication
  • Phinnara Has

    Lifespan Biostatistics, Epidemiology and Research Design, Rhode Island Hospital, Providence, RI 02903, USA

    1 shared publication
  • Rahiya Rehman

    Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics Saint Louis University School of Medicine St. Louis Missouri USA

    1 shared publication
  • Shova Subedi

    Warren Alpert Medical School of Brown University, Hasbro Children’s Hospital , Providence, RI

    1 shared publication

Latest Publications

  • Open Access

    Ustekinumab for anti-tumor necrosis factor refractory pediatric ulcerative colitis: a promising approach towards endoscopic healing

    by Rahiya Rehman, Muhammad Safwan Riaz, Dyadin Esharif, Phinnara Has, Michael Herzlinger, Jason Shapiro, Shova Subedi

    Background/Aims: To describe the role of ustekinumab in inducing remission and endoscopic healing in anti-tumor necrosis factor α nonresponsive pediatric ulcerative colitis patients at a tertiary care inflammatory bowel disease center. Methods: A retrospective chart review was performed on patients with ulcerative colitis receiving ustekinumab. Primary outcome was steroidfree clinical remission at follow-up. Secondary outcomes were biochemical remission and endoscopic healing. Results: Ten children were analyzed; 7 (70%) had ulcerative colitis, and 3 (30%) had inflammatory bowel disease unspecified with colitis. Median follow-up period was 56 weeks. Nine patients (90%) achieved steroid-free clinical remission and biochemical remission. Seven patients had follow-up colonoscopies, out of which 6 (86%) achieved endoscopic remission, while 1 (14%) underwent colectomy. Out of the 3 patients without a follow-up colonoscopy, fecal calprotectin levels downtrended to < 150 mg/kg in 2 patients and < 400 mg/kg in 1 patient from baseline level of > 2,000 mg/kg. Conclusions: Ustekinumab appears efficacious in achieving not only clinical and biochemical remission but also has promising role in inducing endoscopic healing end point in patients who fail other biologics.